DNER and Thrombocytopenia: Notably, the overall remission rate (complete/partial remission or stable disease status) for pan-BET inhibitors is less than 30% in most clinical trials based on current data.117,126–128 This low response rate might have something to do with the intermittent dosing schedule, whose purpose was originally designed to reduce targeted side effects such as thrombocytopenia.117,126,127 The primary challenge encountered in the development of pan-BET inhibitors is balancing the enhancement of drug efficacy with the reduction of side effects.